Diagnosis and Therapy of Ascites in Liver Cirrhosis

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2011 Apr 2

PMID 21455322

Citations 29

Authors

Erwin Biecker

Affiliations

Soon will be listed here.

Abstract

Ascites is one of the major complications of liver cirrhosis and is associated with a poor prognosis. It is important to distinguish noncirrhotic from cirrhotic causes of ascites to guide therapy in patients with noncirrhotic ascites. Mild to moderate ascites is treated by salt restriction and diuretic therapy. The diuretic of choice is spironolactone. A combination treatment with furosemide might be necessary in patients who do not respond to spironolactone alone. Tense ascites is treated by paracentesis, followed by albumin infusion and diuretic therapy. Treatment options for refractory ascites include repeated paracentesis and transjugular intrahepatic portosystemic shunt placement in patients with a preserved liver function. Potential complications of ascites are spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome (HRS). SBP is diagnosed by an ascitic neutrophil count > 250 cells/mm(3) and is treated with antibiotics. Patients who survive a first episode of SBP or with a low protein concentration in the ascitic fluid require an antibiotic prophylaxis. The prognosis of untreated HRS type 1 is grave. Treatment consists of a combination of terlipressin and albumin. Hemodialysis might serve in selected patients as a bridging therapy to liver transplantation. Liver transplantation should be considered in all patients with ascites and liver cirrhosis.

Citing Articles

Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine.

Zheng S, Xue C, Li S, Zao X, Li X, Liu Q Front Pharmacol. 2024; 15:1381476.

PMID: 39081955 PMC: 11286405. DOI: 10.3389/fphar.2024.1381476.

Protocol to evaluate the efficacy and safety of tolvaptan in patients with refractory ascites after liver resection: an open-label, single-arm phase I/II study.

Namba Y, Kobayashi T, Kuroda S, Hashimoto M, Takei D, Fukuhara S Int J Surg Protoc. 2024; 28(1):1-5.

PMID: 38433869 PMC: 10905494. DOI: 10.1097/SP9.0000000000000015.

Development of a Direct Non-Puncture Device for Measuring Portal Venous Pressure during Liver Transplantation-A Swine Model.

Ho K, Huang T, Lin J, Chiang H Biosensors (Basel). 2023; 13(12).

PMID: 38131767 PMC: 10742213. DOI: 10.3390/bios13121007.

From Non-Alcoholic Steatohepatitis (NASH) to Hepatocellular Carcinoma (HCC): Epidemiology, Incidence, Predictions, Risk Factors, and Prevention.

Motta B, Masarone M, Torre P, Persico M Cancers (Basel). 2023; 15(22).

PMID: 38001718 PMC: 10670704. DOI: 10.3390/cancers15225458.

Efficacy, feasibility and safety of TIPS in the treatment of recurrent portal hypertension with variceal bleeding after open splenectomy and esophagogastric devascularization.

Wang Z, Zhang Z, Guo X, Xu W, Wei N, Zhang Q Abdom Radiol (NY). 2023; 50(1):393-399.

PMID: 37184569 DOI: 10.1007/s00261-023-03945-7.

References

Singh N, Gayowski T, Yu V, Wagener M . Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med. 1995; 122(8):595-8. DOI: 10.7326/0003-4819-122-8-199504150-00007. View

Merli M, Valeriano V, Funaro S, Attili A, Masini A, Efrati C . Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol. 2002; 97(1):142-8. DOI: 10.1111/j.1572-0241.2002.05438.x. View

Ricart E, Soriano G, Novella M, Ortiz J, Sabat M, Kolle L . Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol. 2000; 32(4):596-602. DOI: 10.1016/s0168-8278(00)80221-4. View

Runyon B . Care of patients with ascites. N Engl J Med. 1994; 330(5):337-42. DOI: 10.1056/NEJM199402033300508. View

Llach J, Rimola A, Navasa M, Gines P, Salmeron J, Gines A . Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration. Hepatology. 1992; 16(3):724-7. DOI: 10.1002/hep.1840160318. View

Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Zozaya J . Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology. 1995; 21(4):986-94. View

Alessandria C, Debernardi Venon W, Marzano A, Barletti C, Fadda M, Rizzetto M . Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002; 14(12):1363-8. DOI: 10.1097/00042737-200212000-00013. View

Pozzi M, Osculati G, Boari G, Serboli P, Colombo P, Lambrughi C . Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology. 1994; 106(3):709-19. DOI: 10.1016/0016-5085(94)90706-4. View

Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F . Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver. 1993; 13(3):156-62. DOI: 10.1111/j.1600-0676.1993.tb00624.x. View

10.

Rimola A, Garcia-Tsao G, Navasa M, Piddock L, Planas R, Bernard B . Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000; 32(1):142-53. DOI: 10.1016/s0168-8278(00)80201-9. View

11.

Fogel M, Sawhney V, Neal E, Miller R, Knauer C, GREGORY P . Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol. 1981; 3 Suppl 1:73-80. DOI: 10.1097/00004836-198100031-00016. View

12.

Martin-Llahi M, Pepin M, Guevara M, Diaz F, Torre A, Monescillo A . Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134(5):1352-9. DOI: 10.1053/j.gastro.2008.02.024. View

13.

Grange J, Roulot D, Pelletier G, Pariente E, Denis J, Ink O . Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol. 1998; 29(3):430-6. DOI: 10.1016/s0168-8278(98)80061-5. View

14.

Dagher L, Moore K . The hepatorenal syndrome. Gut. 2001; 49(5):729-37. PMC: 1728492. DOI: 10.1136/gut.49.5.729. View

15.

Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L . Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med. 1995; 122(11):816-22. DOI: 10.7326/0003-4819-122-11-199506010-00002. View

16.

Pomier-Layrargues G, Paquin S, Hassoun Z, Lafortune M, Tran A . Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003; 38(1):238-43. DOI: 10.1053/jhep.2003.50276. View

17.

Riggio O, Angeloni S, Salvatori F, De Santis A, Cerini F, Farcomeni A . Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008; 103(11):2738-46. DOI: 10.1111/j.1572-0241.2008.02102.x. View

18.

Brensing K, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H . Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut. 2000; 47(2):288-95. PMC: 1727992. DOI: 10.1136/gut.47.2.288. View

19.

Bureau C, Garcia-Pagan J, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C . Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004; 126(2):469-75. DOI: 10.1053/j.gastro.2003.11.016. View

20.

Runyon B . Paracentesis of ascitic fluid. A safe procedure. Arch Intern Med. 1986; 146(11):2259-61. View